ASH 2012 Video Coverage
Live Coverage from ASH 2012
Patients with IDA with a history of unsatisfactory oral iron therapy appear to benefit from treatment with IV ferumoxytol.
The oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has an "unprecedented single agent overall response rate" in patients with relapsed or refractory mantle cell lymphoma (MCL), interim results of a global phase 2 study reported during the 54th American Society of Hematology Annual Meeting and Exposition.
The combination of the investigational weekly oral, proteasome inhibitor, MNL9708, plus standard dose lenalidomide and dexamethasone has antitumor activity at the recommended phase 2 dose in treatment-naïve patients with multiple myeloma, investigators reported at the 54th American Society of Hematology Annual Meeting and Exposition.
Asparaginase Erwinia chrysanthemi (marketed as Erwinaze) is well tolerated among children and young adults diagnosed with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to the Escherichia coli-derived L-asparaginase (L-ASP), according to compassionate use protocol data presented during the 54th American Society of Hematology Annual Meeting and Exposition. L-ASP is part of standard chemotherapy regimens for ALL.
Adding aspirin therapy to FCR (fludarabine, cyclophosphamide and rituximab) improves outcomes for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to a single-institution study presented during the 54th American Society of Hematology Annual Meeting and Exposition.
Ponatinib treatment is associated with significant molecular response rates among patients intolerant to dasatinib and nilotinib or who have dasatimib- and nilotinib-resistant chronic myeloid leukemia (CML), according to an analysis of data from the open-label multinational phase 2 PACE clinical trial. The analysis was presented during the 54th American Society of Hematology Annual Meeting and Exposition.
Wide variability across U.S. children's hospitals in antifungal use for pediatric acute myeloid leukemia (AML) does not appear to correlate with induction case fatality rates, according to a study presented during the 54th American Society of Hematology Annual Meeting and Exposition.
Among chronic myeloid leukemia (CML) patients, higher imatinib exposures were associated with better overall survival (OS) and event-free survival (EFS), according to an analysis of data from the WORLD CML Registry presented during the 54th American Society of Hematology Annual Meeting and Exposition.
Ponatinib has substantial activity and is generally well tolerated in heavily pretreated patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation.
Quizartinib is a promising treatment for refractory and relapsed acute myeloid leukemia (AML) after second-line chemotherapy or hematopoietic stem cell transplantation (HSCT), according to a cohort analysis of data from an open-label phase 2 safety and efficacy study presented during the 54th American Society of Hematology Annual Meeting and Exposition.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- St John's Wort and Cancer
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Adjuvant Therapy in Renal Cell Carcinoma: Still Riddled With Unknowns
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC